Exercise of Warrants
AIM share code: SKIN
1 August 2019
("Integumen" or "Company")
The following amendment has been made to the 'Exercise of Warrants' announcement released on 1 August 2019 at 11.32am under RNS number 5754H.
The number of shares in issue in the Total Voting Rights section has been corrected to 979,986,902 shares.
All other details remain unchanged.
The full amended text is shown below.
Exercise of Warrants
Integumen announces that it has received notification from a warrant holder to exercise warrants over 2,000,000 shares in the share capital of Integumen ("the Warrant Shares"). The consideration for the exercise of the Warrant Shares amounts, in aggregate, to a cash value of £30,000.
These shares have today been allotted. Application has been made for the Warrant Shares to be admitted to trading on AIM, which is expected to be on or about 7 August 2019. These shares will rank pari passu with the ordinary shares of the Company in issue.
Total voting rights
The Company's total issued share capital, following the issue of the Warrant Shares, will be 979,986,902 ordinary shares. As the Company does not hold any shares in Treasury, this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company following Admission.
Gerard Brandon, CEO
+44 (0) 7340 055 648
SPARK Advisory Partners Limited
Neil Baldwin/Vassil Kirtchev
+44 (0) 113 370 8974
Turner Pope Investments (TPI) Limited (Broker)
+44 (0) 20 3621 4120
Integumen is a vertically integrated business, collaborating their Labskin technology platform with partners in artificial intelligence, clinical research, medical device and life science. These collaborators are building their own technology on top of the Labskin AI backbone. Labskin allows skin-care, health-care, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.
The Company combines data analytics with access to therapeutic operational expertise and offers solutions to our clients, from regulatory approvals, right through to marketing fully tested ingredients that have been certified on our Laboratory grown living human tissue.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.